# Arjungenin

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/arjungenin
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Terminalia arjuna sapogenin, Arjuna triterpene, Arjun sapogenin, T. arjuna triterpenoid, Arjuna bark sapogenin, 23-Hydroxyarjunolic acid derivative

## Overview

Arjungenin is a pentacyclic triterpenoid saponin isolated primarily from the bark of Terminalia arjuna, a tree long used in Ayurvedic cardiology. It exerts cardioprotective effects chiefly by suppressing [mitochondrial](/ingredients/condition/energy) respiratory oxyburst and modulating [oxidative stress](/ingredients/condition/antioxidant) pathways in cardiac tissue.

## Health Benefits

• Cardioprotective effects in preclinical models, attributed to inhibition of respiratory oxyburst processes. [1] • Traditional use suggests potential benefits for coronary artery disease, although this is not supported by clinical trials. [5] • Used in traditional medicine for angina treatment, but lacks direct evidence. [5] • May be beneficial for hypertension, based on traditional usage, not clinical evidence. [5] • General [cardiovascular health](/ingredients/condition/heart-health) benefits noted in Terminalia arjuna reviews, lacking compound-specific studies. [5]

## Mechanism of Action

Arjungenin inhibits the respiratory oxyburst process in mitochondria, reducing superoxide radical generation during ischemia-reperfusion events in cardiac cells. It also modulates NF-κB signaling to downregulate [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6, limiting inflammatory cascades in myocardial tissue. Additionally, arjungenin has been shown to interact with antioxidant enzyme systems, upregulating superoxide dismutase (SOD) and catalase activity, thereby reducing [lipid peroxidation](/ingredients/condition/antioxidant) markers like malondialdehyde (MDA) in preclinical cardiac models.

## Clinical Summary

The evidence base for arjungenin specifically is limited almost entirely to in vitro cell studies and rodent models, with no published randomized controlled trials isolating this compound. Most human clinical data comes from trials using whole Terminalia arjuna bark extract, which contains arjungenin alongside arjunolic acid, arjunetin, and glycosides, making it impossible to attribute outcomes solely to arjungenin. Small open-label studies using T. arjuna bark powder (500 mg twice daily) reported modest improvements in left ventricular ejection fraction and exercise tolerance in patients with stable angina, but these are confounded by the multi-compound extract. Until isolated compound trials are conducted, clinical claims for arjungenin specifically must be considered preliminary and largely inferential from traditional use and preclinical data.

## Nutritional Profile

Arjungenin is not a nutrient or food substance but rather a triterpenoid sapogenin (oleanane-type pentacyclic triterpenoid) isolated primarily from the bark of Terminalia arjuna. Its molecular formula is C₃₀H₄₈O₅ (molecular weight ~488.7 g/mol). It is the aglycone (non-sugar) moiety of arjunic acid glycosides and arjunoside saponins. Typical concentrations in T. arjuna bark extract range from approximately 0.01–0.1% w/w of dried bark, depending on extraction method and plant source. Key bioactive structural features include a free carboxylic acid group at C-28, hydroxyl groups at C-2α, C-3β, and C-19α (or C-23), and an oleanene skeleton. It is a lipophilic compound with limited aqueous solubility, which constrains oral bioavailability; estimates suggest poor to moderate absorption without formulation enhancement. It contains no macronutrients (protein, carbohydrates, fat), no dietary fiber, and no vitamins or minerals. Its pharmacological relevance is entirely attributable to its triterpenoid scaffold. Related co-occurring bioactives in T. arjuna bark include arjunolic acid (~0.1–0.5% w/w), arjunoside I–IV (glycosylated forms), arjunic acid, gallic acid (~1–2% w/w), ellagic acid (~0.5–1.5% w/w), and oligomeric proanthocyanidins (~5–15% w/w). Bioavailability may be improved via lipid-based delivery systems, nanoformulations, or co-administration with piperine or phospholipid complexes, though specific pharmacokinetic data for arjungenin in humans remain sparse.

## Dosage & Preparation

No clinically studied dosage ranges are available for arjungenin in any form due to the absence of human trials. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Arjungenin and T. arjuna preparations are generally considered well-tolerated at conventional doses, with mild gastrointestinal discomfort being the most commonly reported side effect in observational reports. Due to its vasodilatory and hypotensive potential, arjungenin may interact with antihypertensive medications such as beta-blockers, ACE inhibitors, and calcium channel blockers, potentially causing additive [blood pressure](/ingredients/condition/heart-health) lowering. Patients on anticoagulant or antiplatelet therapy, including warfarin or aspirin, should exercise caution as T. arjuna extracts have demonstrated mild platelet aggregation inhibition in preclinical studies. Safety data in pregnancy and lactation is absent, and use should be avoided in these populations until adequate research is available.

## Scientific Research

Currently, no human clinical trials, randomized controlled trials, or meta-analyses for arjungenin are available. Research is limited to in vitro and animal studies. No PMIDs are provided for clinical trials.

## Historical & Cultural Context

Arjungenin is part of the Terminalia arjuna bark, historically used in Ayurveda for [cardiovascular health](/ingredients/condition/heart-health), including coronary artery disease and hypertension. Its use spans centuries in Indian traditional medicine.

## Synergistic Combinations

Arjunic acid, Arjunolic acid, Arjunglucoside I, Arjunglucoside II, Arjunetin

## Frequently Asked Questions

### What plant does arjungenin come from?

Arjungenin is extracted from the bark of Terminalia arjuna, a deciduous tree native to the Indian subcontinent. The bark has been used for over 3,000 years in Ayurvedic medicine under the system of 'Charaka Samhita' for treating heart conditions, and arjungenin is considered one of its principal bioactive triterpene constituents alongside arjunolic acid and arjunetin.

### Is arjungenin the same as arjunolic acid?

No, arjungenin and arjunolic acid are distinct pentacyclic triterpenoids that both occur in Terminalia arjuna bark. Arjunolic acid (2α,3β,23-trihydroxyolean-12-en-28-oic acid) is more extensively studied and carries a carboxylic acid functional group, whereas arjungenin has a different hydroxylation pattern and slightly different pharmacological profile, though both demonstrate antioxidant and cardioprotective activity in preclinical models.

### Can arjungenin help with coronary artery disease?

Traditional Ayurvedic medicine has long used Terminalia arjuna bark, which contains arjungenin, for coronary artery disease and angina management. However, no clinical trials have specifically isolated arjungenin's effect on coronary artery disease in humans; the supporting evidence remains preclinical, involving rodent ischemia-reperfusion models where it reduced infarct size and improved cardiac enzyme profiles such as CK-MB and LDH.

### What is the typical dosage of arjungenin or Terminalia arjuna containing it?

There is no established clinical dosage for isolated arjungenin because it has not been studied as a standalone supplement in human trials. Standardized Terminalia arjuna bark extract, which contains arjungenin as one constituent, is typically used at 500 mg two to three times daily in observational studies and traditional practice, though the exact arjungenin content per dose varies significantly by extraction method and is rarely standardized on product labels.

### Does arjungenin have antioxidant properties?

Yes, arjungenin demonstrates significant antioxidant activity in preclinical studies, primarily by upregulating endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase, and glutathione peroxidase in cardiac and hepatic tissue. In rodent models, arjungenin treatment significantly reduced malondialdehyde (MDA) levels, a marker of lipid peroxidation, suggesting it combats oxidative stress through both direct free radical scavenging and indirect enzyme-mediated mechanisms.

### Does arjungenin interact with blood pressure or heart medications?

Arjungenin may have potential interactions with cardiovascular medications, particularly those affecting blood pressure or heart function, since it demonstrates cardioprotective activity in preclinical models. If you are taking antihypertensive drugs, anticoagulants, or cardiac glycosides, consult a healthcare provider before adding arjungenin supplements to avoid additive effects or reduced medication efficacy. Clinical interaction studies are limited, making direct medical supervision advisable for those on multiple heart medications.

### Is arjungenin safe to take during pregnancy or while breastfeeding?

There is insufficient safety data on arjungenin use during pregnancy or lactation, and it should be avoided in these populations until more research is available. Traditional use of Terminalia arjuna in pregnancy has not been validated by modern clinical trials. Pregnant or breastfeeding individuals should consult a healthcare provider before using any supplement containing arjungenin.

### How strong is the scientific evidence supporting arjungenin's cardiovascular benefits?

Arjungenin shows promise in preclinical (laboratory and animal) models for cardioprotective effects through inhibition of respiratory oxyburst processes, but clinical trial evidence in humans is lacking or limited. Most cardiovascular claims for arjungenin are based on traditional medicine use rather than rigorous human studies. More high-quality clinical research is needed to establish efficacy and safe dosing in patients with specific heart conditions.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*